How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,090 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. GABA Pathways in Autism Spectrum Disorder (ASD)

), medroxyprogesterone injections (e.g. Depo-Provera), etonogestrel implants (e.g., Implanon, Norplan), normal and low dose combined oral contraceptive pills, norelgestromin / EE transdermal system, intravaginal device (e.g., EE and etonogestrel) and desogestrel (Cerazette). Pregnancy or breastfeeding (is a routine exclusion for research MRI scanning). Female study participants must be willing to use one form of highly effective non-hormonal contraception for one week after study drug administration. This would

2018 Clinical Trials

82. Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir

participant report at Screening, regular menstrual cycles with at least 21 days between menses Note: This criterion is not applicable to participants who report using a progestin-only method of contraception at Screening (e.g., Depo-Provera or levonorgestrel-releasing IUD) nor to participants using continuous combination oral contraceptive pills, as the absence of regular menstrual cycles is an expected, normal consequence in this context. Per participant report at Screening and Enrollment, states

2018 Clinical Trials

83. National Adaptive Trial for PTSD Related Insomnia

be willing to use a reliable form of contraception for 16 weeks (during study treatment and for 2 weeks after taking the last dose) which includes: barrier contraceptives (male or female condoms with or without a spermicide, diaphragm or cervical cap with spermicide, or intrauterine device) and hormone-based therapy (contraceptive pills, intrauterine devices, or Depo-Provera�) Birth control for female participants is not necessary if surgically sterile or if with a partner with whom they are not capable

2018 Clinical Trials

84. Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

by the investigator or designee). A highly effective form of birth control includes true sexual abstinence, a vasectomized sexual partner, Implanon®, female sterilization by tubal occlusion, any effective intrauterine device (IUD)/levonorgestrel intrauterine system (IUS), Depo-Provera (trademark) injections, oral contraceptive and Erva Patch (trademark) or Nuvaring (trademark) Women of childbearing potential (after menarche) must agree to use a highly effective form of birth control, as defined above, from

2018 Clinical Trials

85. Relative Bioavailability Study of Zoloft Oral Solution to Zoloft Tablets

, progesterone releasing intrauterine devices [IUDs], vaginal ring, and postcoital contraceptive methods), and hormone replacement therapy must have been discontinued at least 28 days prior to the first dose of investigational product. Depo Provera must have been discontinued at least 6 months prior to the first dose of investigational product. Consumption of grapefruit or grapefruit related citrus fruits (eg, Seville oranges, pomelos) or juices within 7 days prior to dosing. Blood donation (excluding plasma

2018 Clinical Trials

86. A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous Administration of TV46046

(decompensated) or liver tumors has known significant renal disease has a history of diagnosed clinical depression or bipolar disorder, with or without suicidal ideation, and/or history of suicide attempt is currently using hormonal contraception had an injection of DMPA (Depo-Provera CI or Depo-subQ 104) in the past 12 months; or combined injectable in the last 3 months is chronically using pain medication has a plan to move to another location in the next 18 months Additional criteria apply, please contact (...) Administration of TV-46046 Actual Study Start Date : January 15, 2019 Estimated Primary Completion Date : June 17, 2020 Estimated Study Completion Date : June 17, 2020 Arms and Interventions Go to Arm Intervention/treatment Experimental: TV-46046 - 1 One of 24 sequences Drug: TV-46046 - 1 120 mg/0.3 mL Drug: TV-46046 - 2 60 mg/0.3 mL of 1:1 saline-diluted TV-46046 Drug: medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL (injectable suspension) Other Name: Depo-subQ 104 Drug: TV-46046 Placebo

2018 Clinical Trials

87. Daily Liraglutide for Nicotine Dependence

as "intend to quit within one month"). Body mass index (BMI) greater than or equal to 27 kg/m2 with one weight-related comorbidity (e.g. high blood pressure, high cholesterol, dyslipidemia) or greater than or equal to 30 kg/m2 per the manufacturer label for weight management. Women of childbearing potential (based on medical history) must consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, intrauterine

2018 Clinical Trials

88. Knowledge and utilization of family planning methods among people living with HIV in Kathmandu, Nepal. (Full text)

to all of the eligible participants.The mean ± SD age of the participants was 36.62 ± 7.58 years. Sixty five percent of the respondents' spouses were HIV positive. A majority of the respondents (72%) had heard of seven modern family planning methods. Considerably high number (72%) of the respondents or their spouses were using at least one of the method of family planning. The most common method was condom (83%) and the least common was IUCD (0.50%). The use of short acting (pills, depo-provera

2018 BMC Health Services Research PubMed abstract

89. "It is my business": A Mixed-Methods Analysis of Covert Contraceptive Use among Women in Rakai, Uganda. (Full text)

"It is my business": A Mixed-Methods Analysis of Covert Contraceptive Use among Women in Rakai, Uganda. Covert contraceptive use (CCU) is the use of family planning without a partner's knowledge. This study sought to examine CCU prevalence among women living in Rakai, Uganda, predictors of CCU, and why women resort to CCU.We used data from women (15-49years) currently using contraceptives (oral contraceptives, Depo Provera, implants, intrauterine devices, and periodic abstinence) during Round

2018 Contraception PubMed abstract

90. Low Dose Fat-Induced Insulin Resistance

Estimated glomerular filtration rate < 55 ml/min/1.73 m2 (calculated using the subject's measured serum creatinine and the Modification of Diet in Renal Disease [MDRD] study estimation formula). Presence of soy or egg allergies (due to possible reactions with fat infusate) For female participants: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices

2018 Clinical Trials

91. Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity

form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms

2018 Clinical Trials

92. Intranasal Oxytocin and Food Intake in Obese Adolescents

(Child, Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Proficient in English. Pubertal or Post-Pubertal Females: 13 to <18 years. Pubertal or Post-Pubertal Males: 15 to <20 years. Girls must have a negative urine pregnancy test and post-menarchal girls must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study. Currently obese (BMI

2018 Clinical Trials

93. Reproductive Health Outcomes by Method of Breast Milk Feeding

pregnancy planning to initiate a hormonal contraceptive method at the postpartum visit At time of delivery hospitalization, a second eligibility verification will occur and women will be excluded if they: initiated a hormonal contraceptive method (specifically intrauterine device, implant, depo provera injections) during the delivery hospitalization had a hysterectomy did not deliver at UC Davis are no longer interested in study participation SUB-STUDY Inclusion Criteria: enrolled in the main study

2018 Clinical Trials

94. Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

, etc.) Have an identified secondary cause of ovarian insufficiency Have POI in the setting of Turner syndrome, Fanconi Anemia, galactosemia, or Perrault syndrome (as associated neurological/medical sequelae could confound baseline measures) Have used medications known to affect bone metabolism over previous 3 months (e.g. anticonvulsants, chronic use of glucocorticords, Depo-Provera, oral contraceptive pills) Be currently pregnant (to be confirmed by pregnancy testing) Inclusion Criteria (...) of glucocorticoids, Depo-Provera, oral contraceptive pills, etc.) Have a learning disability or a developmental delay Be currently taking any SSRIs, antipsychotics or have any documented problems with anxiety or depression. Be currently pregnant (as confirmed by pregnancy testing) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2018 Clinical Trials

95. Effect of Benralizumab in Atopic Dermatitis

not be actively seeking pregnancy, and must use an effective form of birth control (confirmed by the Investigator). Effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD)/ levonorgestrel Intrauterine system (IUS), Depo-Provera™ injections, oral contraceptive, and Evra Patch™ or Nuvaring™. WOCBP must agree to use effective method of birth control, as defined above, from enrolment

2018 Clinical Trials

96. Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

options include: surgical sterilization (patient and/or patient's partner), approved hormonal contraceptives or therapies (such as birth control pills, Depo-Provera, or Lupron Depot), barrier methods (such as a condom or diaphragm) used with a spermicide, and an intrauterine device (IUD). Exclusion Criteria: Unwillingness or inability (such as coagulopathy) to undergo serial prostate biopsy. History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated

2018 Clinical Trials

97. An Intermediate Expanded Use Trial of DFMO

after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended. Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines Exclusion

2018 Clinical Trials

98. The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes

the study. Acceptable contraception methods include: Oral contraceptive pill (OCP), Intrauterine Device (IUD, hormonal or copper), Male condoms, Female condoms, Diaphragm or cervical cap with spermicide, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis Need to go outside of the designated geographic boundaries during

2018 Clinical Trials

99. Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

combined oral pills Hormonal shot or injection (eg, Depo-Provera) Intrauterine system device (eg, levonorgestrel-releasing intrauterine system -Mirena®) Norelgestromin/ethinyl estradiol transdermal system Intravaginal device (eg, ethinyl estradiol and etonogestrel) Cerazette (desogestrel). Cerazette is currently the only highly efficacious progesterone based pill. Side effects of previous treatments have not resolved to grade 1 or less, with the exception of alopecia that is considered related

2018 Clinical Trials

100. Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

after the last study drug administration. Effective contraceptive methods include: Barrier methods such as condom, sponge or diaphragm combined with spermicide in foam, gel or cream; Hormonal contraception (oral, intramuscular, implant or transdermal) which include Depo Provera, Evra and Nuvaring; and Intrauterine device (IUD). Patients must be capable of giving informed consent and the consent must be obtained prior to any study related procedures. Exclusion criteria Patient with BSA > 15

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>